7
Nov
2019

Takeda’s Busy Week, Halozyme’s Stumble, and New FDA Commish On Deck

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal
Amgen’s Bet on BeiGene, David Hung’s Megaround, & Zolgensma Speed Bump
Vertex’s Watershed for CF, Biogen’s Head-Scratcher, and Seattle Genetics Nails HER2Climb
Reata Booms, Alexion Buys Achillion, & Teva Drops the Ball (Big Time)